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Abstract
Objectives. Effective management of axial spondyloarthritis (axSpA)-related fatigue is a major unmet clinical need.
Anti-TNF therapy may reduce fatigue levels, although any effect has yet to be definitively quantified and predictors
of any such improvements are unknown.
Methods. The British Society of Rheumatology Register in Axial Spondyloarthritis (BSRBR-AS) prospectively
recruited axSpA patients across the UK. Changes in fatigue levels (measured using the Chalder Fatigue Scale)
>1 year were compared between those starting anti-TNF therapy at the time of recruitment and those not.
Differences between treatment groups were adjusted using propensity score matching. Results were meta-analysed
with the extant literature to calculate pooled estimates. Then, among those BSRBR-AS anti-TNF commencers with
clinically relevant fatigue, baseline predictors of response were investigated.
Results. Of the 998 BSRBR-AS recruits with complete fatigue data, 310 were anti-TNF commencers. At 1-year
follow-up, the former group reported a mean fatigue change of 2.6 (95% CI 4.1, 1.9) points while the latter
reported a mean worsening of fatigue by 0.2 points. Following propensity score adjustment, those commencing anti-
TNF therapy reduced fatigue by 3.0 points compared with those not. Of those with significant fatigue and commencing
anti-TNF, poor sleep quality at baseline predicted fatigue improvement. In the meta-analysis, including 1109 subjects,
treatment with anti-TNF therapy resulted in a significant improvement in fatigue [Standardized mean difference (SMD) ¼
0.36, 95% CI 0.15, 1.56].
Conclusion. Anti-TNF therapy results in a significant but modest reduction in fatigue amongst axSpA patients,
with those reporting poor sleep quality most likely to report improvement. Effective management will likely require
additional approaches.
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Introduction
Fatigue represents a critical priority among patients with
axial spondyloarthritis (axSpA) [1]. This pervasive symp-
tom, reported by 50–65% of patients [2, 3], is a principal
determinant of impaired quality of life [3]. Although the
EULAR 2016 guidelines state that the primary focus of
axSpA management is to improve quality of life [4], no
specific interventions are currently recommended for
axSpA-related fatigue.
Anecdotally there are patients who report substantial
improvements in their fatigue following anti-TNF therapy.
Certainly, there are randomized controlled trials (RCT)
where fatigue has been recorded as a secondary
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outcome that have reported clinically significant fatigue
reductions in comparison to placebo [5]. However, there
appears to be considerable variability between studies;
for example, Dougados et al. [6] failed to identify a sig-
nificant fatigue benefit in their trial of etanercept. Given
the heterogeneous nature of this symptom, it may be
that only specific sub-groups of patients experience
meaningful reductions in fatigue, although the character-
istics of any such groupings have yet to be elucidated.
Using the real-world British Society of Rheumatology
Register in Axial Spondyloarthritis (BSRBR-AS) registry,
we aimed to quantify the effect of anti-TNF therapy on
fatigue among axSpA patients and to then synthesize
these findings with existing studies in a meta-analysis.
We then sought to characterize those axSpA patients
who experienced a meaningful improvement in fatigue
following anti-TNF therapy.
Methods
BSRBR-AS analysis
Data were obtained from a UK-wide prospective cohort
study, the BSRBR-AS. The BSRBR-AS study recruited
approximately 2500 patients who met the Assessment
of SpondyloArthritis International Society for radiograph-
ic or non-radiographic axSpA from 83 centres across
the UK between 2012 and 2017. Eligible patients com-
mencing anti-TNF therapy were assigned to the ‘biolog-
ics’ sub-cohort, the remainder to the ‘non-biologics’
sub-cohort. Detailed methodology of the BSRBR-AS
study can be found in the study protocol, which has
been published previously [7].
Clinical data were entered into electronic Case Report
Forms collected at recruitment, routine clinical visits and
at 12-month follow-up. Patients were also invited to com-
plete survey questionnaires that included demographic in-
formation, Bath disease assessment indices [8], sleep
quality [9], anxiety/depression [10] and quality of life [11].
For this study, our outcome of interest was fatigue,
measured using the Chalder Fatigue Scale (CFS) [12].
This 11-item questionnaire is one of the most commonly
employed measures of fatigue. Validated in both general
and clinical populations [13], it examines physical and
mental fatigue dimensions. Items are rated on a four-
point (0–3) Likert scale (0 ¼‘better than usual’, 1 ¼‘no
worse than usual’, 2 ¼‘worse than usual’ and 3 ¼‘much
worse than usual’). The scores are totalled (0–33), with
higher scores indicating greater fatigue. A reduction of
2 is considered clinically important when used to
evaluate treatment response [14]. In addition, by dichot-
omizing individual question responses at the median, a
bimodal fatigue score can be generated ranging from 0
to 11 to classify fatigue where >3 is considered to be
clinically important [12].
Participants who had completed the fatigue scale at
baseline and 12 (3) month follow-up were eligible for this
analysis. Analysis was conducted on the June 2017
download of data.
The study complies with the Declaration of Helsinki.
Ethical approval was granted by the National Research
Ethics Service Committee North East – County Durham
and Tees Valley (Research Ethics Committee reference
– 11/NE/0374). Appropriate National Health Service
(NHS) Research and Development approvals were
obtained for each site and inform consent obtained.
In order to quantify the effect of anti-TNF therapy on
fatigue in the BSRBR-AS, we examined the change in fa-
tigue between baseline and 12 months for the ‘biologic’
and ‘non-biologic’ cohorts using the Likert CFS scale. In
observational studies, treatment assignment is not ran-
dom and large differences in observed covariates are
likely to exist between patients who received biologic
therapy and patients who did not. This decision to com-
mence biologic therapy is often influenced by patient
factors and clinical characteristics such as disease activ-
ity. Therefore, a direct comparison of the two clinical
cohorts can lead to confounding by indication. To reduce
this bias, we carried out propensity score matching,
introduced by Rosenbaum and Rubin [15]. A logistic re-
gression model was used to estimate a propensity score
modelled by covariates that represented subject charac-
teristics at recruitment (baseline): age, gender, smoking
status, disease duration and serum CRP. Therefore, the
propensity score is the probability of receiving a treat-
ment conditional on a vector of observed covariates [15].
After adjusting for observed differences between the bio-
logic and non-biologic sub-cohorts, an independent t
test was used to compare the mean changes in fatigue.
We next examined the mean changes in fatigue be-
tween treatment groups among selected patients with
clinically significant baseline fatigue (CFSbimodal >3).
Regression models were then employed to explore uni-
variate predictors of clinically important fatigue response
(change in score 2 on CFSlikert) among this subgroup of
patients. All data analyses were performed using STATA
version 14.0 (StataCorp, College Station, TX, USA).
Systematic review and meta-analysis
Electronic databases: Ovid MEDLINE, EMBASE,
Evidence Based Medicine, and Cochrane Library, were
searched up to October 2018. A detailed search strat-
egy can be found in Supplementary material, available
at Rheumatology online. The Preferred Reporting Items
for Systematic Reviews and Meta-Analyses statement
was used to guide the conduct and reporting of this
systematic review and meta-analysis [16].
Inclusion criteria were based on the following:
. population: adults with axSpA or AS by recognized cri-
teria/clinical diagnosis;
. study design: observational studies (longitudinal pro-
spective and retrospective studies with follow-up),
RCTs and quasi RCTs were included. RCTs compared
a biologic with or without a conventional DMARD
(csDMARD) against a placebo with or without the same
csDMARD; and
. outcomes: there must be a measure of fatigue reported
either before or at the time of commencing biologic
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treatment and after, that is, quantitative results to allow
change in fatigue to be measured.
Potentially eligible abstracts were independently
screened by two reviewers (M.K., J.S.) and any dis-
agreements were resolved by discussion. Relevant data
from included studies were extracted by M.K. and
cross-checked by a second reviewer (J.S.). Where stud-
ies were potentially eligible but data presented in the
manuscript did not allow for inclusion in the meta-
analysis, authors of the study were contacted to request
for data.
For continuous outcome variables, the mean differ-
ence of change in fatigue parameters was calculated
with 95% CIs. Heterogeneity was assessed using the
Chi-square statistic. Where there was evidence of mod-
erate-to-high heterogeneity (I2 >40%), results were ana-
lysed using a random-effects model.
Results
The effect of anti-TNF on fatigue in the BSRBR-AS
Of the 2420 BSRBR-AS subjects, 998 had completed
the fatigue questionnaire at both baseline and 12-
month follow-up. There were no clinically significant
differences between those analyses and those
excluded (Supplementary Table 1, available at
Rheumatology online>). Of these, 310 were recruited to
the ‘biologic cohort’ (28% etanercept, 68% adalimu-
mab, 4% certolizumab) and 688 to the ‘non-biologic
cohort’. Many baseline characteristics of the cohorts
were similar (Table 1), although subjects starting anti-
TNF therapy were significantly younger (47 vs 54 years)
with lower disease duration (9 vs 16 years). They were
also more likely to be smokers (21% vs 11%). Average
fatigue levels at study entry were similar between
cohorts (3.4 vs 2.7 points). Over the 12-month follow-
up period, 82% of the biologic cohort remained on
anti-TNF.
Subjects starting anti-TNF for axSpA reported a 2.6-
point reduction of fatigue after 1 year (95% CI 4.1,
1.9) with no significant differences between agents. In
contrast, the non-biologic cohort reported a 0.4-point in-
crease in fatigue. Following propensity score adjust-
ment, the difference (3.0 points, 95% CI 4.1, 1.9)
was statistically significant (Table 2).
Meta-analysis of anti-TNF effect on axSpA fatigue
The search strategy initially identified 443 manuscripts
of which only four (involving 805 participants) met eligi-
bility criteria for inclusion in the meta-analysis (see
Fig. 1). Of these, three were multicentre RCTs and one
an observational study, with follow-up ranging between
four and 32 weeks (see Supplementary Table 2, available
at Rheumatology online).
Due to a variation in fatigue measures between stud-
ies, standardized mean differences were computed.
Overall, anti-TNF treated axSpA subjects experienced a
small but significant improvement in fatigue in compari-
son to non-biologically treated axSpA subjects (SMD ¼
0.36, 95% CI 0.15, 1.56) (Fig. 2). A high level of hetero-
geneity was observed (I2 ¼64.5%).
Characteristics of fatigue responders in the
BSRBR-AS
Within the BSRBR-AS biologics cohort, 205 (66%)
subjects reported clinically significant fatigue at base-
line. Of these, 139 (68%) experienced a clinically rele-
vant improvement in their fatigue at 1 year. These
TABLE 1 BSRBR-AS study: baseline characteristics of biologic and non-biologic cohorts
Continuous factors Biologic cohort
(n5 310)
Non-biologic cohort
(n5688)
Differencea
(95% CI)
Male, % 67.4 70.6 3.2 (9.4, 3.1)
Age (mean), years 46.9 53.6 6.7 (7.2, 6.2)
Disease duration (mean), years 9.2 15.7 6.4 (6.9, 6.0)
Current smokers, % 20.9 10.8 10.1 (5.0, 15.2)
Employed, % 63.1 59.0 4.1 (2.4, 10.6)
CRP, mg/dL 25.3 22.8 2.5 (1.4, 3.6)
Disease activity—BASDAI [scored 0 (best) to 10 (worst)] 6.2 3.7 2.6 (2.4, 2.8)
Disease activity—ASDAS (higher score ¼ worst disease activity) 3.6 2.5 1.0 (0.9, 1.2)
BASFI [scored 0 (best) to 10 (worst)] 6.1 3.7 2.4 (2.2, 2.6)
BAS-G [scored 0 (best) to 10 (worst)] 7.0 3.7 3.3 (3.1, 3.4)
Spinal pain [scored 0 (best) to 10 (worst)] 6.1 3.2 2.9 (2.7, 3.1)
ASQoL [scored 0 (best) to 18 (worst)] 11.6 6.0 5.6 (5.3, 5.9)
Sleep disturbance [scored 0 (best) to 20 (worst)] 12.8 8.6 4.2 (3.9, 4.6)
Fatigue [scored 0 (best) to 11 (worst)] 3.4 2.7 0.7 (0.4, 1.0)
Anxiety (HADS) [scored 0 (best) to 21 (worst)] 8.7 6.2 2.5 (2.2, 2.8)
Depression (HADS) [scored 0 (best) to 21 (worst)] 7.2 4.6 2.7 (2.4, 2.9)
aDifference ¼ biologic–non-biologic cohort. ASDAS: assessment of spondyloarthritis disease activity score; ASQoL: AS
quality of life index; VAS: visual analogue scale; HADS: hospital anxiety and depression scales.
AxSpA-related fatigue and anti-TNF
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subjects were significantly more likely to report poor
sleep and high fatigue levels at baseline. Baseline
CRP was not significantly related to fatigue response
(Table 3).
Discussion
Anti-TNF therapy is associated with a significant, albeit
small, improvement in fatigue among patients with
axSpA. Patients with sleep difficulties appear marginally
TABLE 2 BSRBS-AS study: changes in fatigue between biologic and non-biologic cohort (matched by propensity score)
Biologic
cohort
Non-biologic
cohort
Mean difference in
change (95% CI)
Change in fatigue (whole cohort) 2.6 0.4 3.0 (4.1, 1.9)
Change in fatigue (clinically significant fatigue at baseline) 4.1 1.2 2.8 (4.3, 1.3)
FIG. 1 PRISMA flowchart of study selection and inclusion
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more likely to experience a clinically relevant reduction
in fatigue following this intervention.
The precise mechanisms of axSpA-related fatigue
are unknown. Biologically, pro-inflammatory cytokines
such as TNFa are implicated in the generation of sick-
ness behaviours – a constellation of body responses to
inflammation of which fatigue is salient [17]. However,
observational studies have identified multiple associa-
tions, implying a multi-factorial origin, with systemic in-
flammation not consistently relating to fatigue [18, 19].
Thus, the observed improvements following anti-TNF
therapy may be partly derived indirectly from improve-
ments in pain, sleep disturbance and mental health
[18–20].
The modest effect of anti-TNFa on axSpA-related fatigue
aligns with a recent uncontrolled observational study that
reported general improvements in fatigue scores following
treatment with this therapy; however, 80% of patients still
experienced severe fatigue at 3 months follow-up [21].
Therefore, if such a pharmacological approach is to ever be
usefully clinically applied for axSpA fatigue, it will have to be
directed towards select sub-populations.
In the BSRBR-AS cohort reported here, poor sleep
appears to predict fatigue response to anti-TNFa. We
speculate that those patients with a combination of fa-
tigue and sleep disturbance identify themselves as
maintaining a sickness behaviour-like endotype. Both
subjective [18, 20] and objective polysomnographic
measures of sleep quality [22] have previously been
related to fatigue in this clinical population. Moreover,
there is also accumulating evidence that TNFa is a key
sleep regulatory molecule that mediates both sleep-pro-
moting and inhibitory neural circuits [23]; indeed, axSpA
patients consistently report improvements in their sleep
following prescription of anti-TNFa therapy [24, 25].
While affording some putative biological insights, the
prediction effect is modest and so any endotype will
likely represent a small, clinically less useful, subgroup.
The similarities in prevalence and impact of fatigue
across inflammatory rheumatic diseases have led to the
plausible suggestion that pathophysiology is shared. In
line with this, the fatigue effect size reported here is
comparable to that observed following cytokine targeted
FIG. 2 Forest plot of fatigue change differences between
patients receiving biologics and non-biologics
TABLE 3 BSRBR-AS: Univariate factors associated with improvement in fatigue amongst those with clinically significant
fatigue at baseline
Likelihood of improvement
Continuous factors Coefficient (95% CI)
Age 0.01 (0.02, 0.02)
CRP, mg/l 0.002 (0.004, 0.01)
Disease Activity—BASDAI (no fatigue) [scored 0 (best) to 10 (worst)] 0.01 (0.14, 0.16)
Disease Activity—ASDAS (higher score ¼ worst disease activity) 0.12 (0.19, 0.43)
BASFI [scored 0 (best) to 10 (worst)] 0.02 (0.11, 0.15)
BAS-G [scored 0 (best) to 10 (worst)] 0.03 (0.16, 0.22)
Spinal pain [scored 0 (best) to 10 (worst)] 0.09 (0.23, 0.04)
ASQoL [scored 0 (best) to 18 (worst)] 0.02 (0.09, 0.06)
Fatigue [scored 0 (best) to 11 (worst)] 0.16 (0.03, 0.30*)
Sleep disturbance [scored 0 (best) to 20 (worst)] 0.07 (0.02, 0.12*)
Anxiety (HADS) [scored 0 (best) to 21 (worst)] 0.05 (0.12, 0.02)
Depression (HADS) [scored 0 (best) to 21 (worst)] 0.01 (0.09, 0.07)
WPAI_absenteeism (scored as percentage of previous week) 0.01 (0.01, 0.02)
WPAI_presenteeism (scored as percentage of previous week) 0.01 (0.03, 0.01)
WPAI_work impairment (scored as percentage of previous week) 0.01 (0.02, 0.01)
WPAI_activity impairment (scored as percentage of previous week) 0.001 (0.01, 0.01)
Dichotomous factors Odds ratio (95% CI)
Gender (female vs male) 0.70 (0.37, 1.27)
Work status (yes vs no) 1.42 (0.78, 2.59)
Job type (mainly physical vs mainly sedentary) 0.48 (0.22, 1.06)
Concurrent FM (2011 mod. of ACR2010 criteria: yes vs no) 0.75 (0.22, 2.52)
ASQoL: ankylosing spondylitis quality of life index; HADS: hospital anxiety and depression scales; WPAI: work productivity
and activity impairment scale. *P <0.05.
AxSpA-related fatigue and anti-TNF
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biological therapy in RA [26] and PsA [27]. In practical
terms, this further supports the future pragmatic delivery
of generic rather than disease-specific management
approaches.
These data should be interpreted in the context of a
number of limitations. First, significant heterogeneity
existed between the studies identified within the system-
atic review. All studies, however, evidenced a positive
effect on fatigue and no studies reported a substantial
benefit. Secondly, the fatigue outcome measure varied
between studies that required the computation of stand-
ardized mean differences. Thirdly, assessing outcomes
at multiple time points would have been ideal. BSRBR-
AS fatigue outcomes were restricted to the 1-year
follow-up visit due to inadequate available data at other
time points, while follow-up across the other studies
ranged between 1 and 24 months. The overall effect is
unlikely to be greatly influenced by such variation be-
cause anti-TNFa response is generally stable after
3 months [28] and only the small Wanders study
restricted follow-up to less than 3 months. A sensitivity
analysis excluding this study recorded a similar overall
estimate (SMD ¼ 0.35, 95% CI 0.12, 0.58). Fourthly,
none of the selected studies were primarily designed to
evaluate fatigue response in the target population; that
is, axSpA patients experiencing important fatigue.
Instead only patients with high disease activity were
recruited, regardless of fatigue status. We have identi-
fied high baseline fatigue as a predictor of response and
by corollary would anticipate enhanced anti-TNF effects
within this clinically relevant subgroup. Moreover, be-
cause it is unlikely that a RCT testing anti-TNF with the
primary aim of alleviating fatigue will ever be conducted,
the present evidence is likely the best achievable.
Fifthly, the high numbers of excluded patients relate to
high levels of missing fatigue data in the registry. This
may introduce issues of external validity, although no
major clinical differences were observed between those
included and excluded. Finally, propensity scoring can-
not entirely remove concerns regarding confounding by
indication. It is, however, reassuring that the BSRBR-AS
estimates are positioned in between those extracted
from randomized controlled trials.
In summary, although many axSpA patients with ac-
tive disease appear to experience a clinically meaningful
fatigue response following anti-TNF therapy, the size of
benefit is modest. These data further emphasize the
multi-factorial basis of fatigue in axSpA. TNFa pathways
may primarily support the maintenance of fatigue in a
specific subgroup of patients. The combination of poor
sleep quality and fatigue may distinguish such patients.
Future research, primarily designed to investigate fa-
tigue, should seek to better classify this strata. Such an
approach will inform a truly personalized medical ap-
proach to managing this patient priority.
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